HIV

Virologic suppression was similar between the long-acting and once-daily treatments for HIV, but participants were more satisfied with the former.

Lenacapavir, combined with broadly neutralizing HIV antibodies, found effective at viral suppression in patients with HIV.

The latest data indicate that the formulation can provide up to 6 months of full protection against multiple virus challenges.

Study findings confirmed that in asthma, chronic obstructive pulmonary disease, HIV, and influenza, census data differed from the epidemiological data.

Participants also generally prefer newer injectable pre-exposure prophylaxis compared to pills for HIV prevention.

Apretude is an antiretroviral drug that inhibits HIV replication by binding to the active site of integrase and blocking the strand transfer step of retroviral DNA integration.

Pharmacists play an important role in providing education and support with adherence to PrEP in populations with a high risk for HIV infection.

Data from a recent survey reflect a resounding shift toward the role of pharmacies becoming sites for primary care.

Independent, scheduled review of Phase 3 Mosaico clinical trial finds a lack of efficacy in preventing the infection.

NRTIs TAF and TDF are increasingly being used as preexposure prophylaxis (PrEP) to prevent HIV around the world.

The report highlights the growth of personalized medicines with improved efficacy for rare, previously untreatable diseases.

Herpes simplex virus type 2 is a common infection that is largely considered innocuous, but the study estimates that the economic burden may be substantial.

Study finds a strong decline in hepatitis C incidence in the years immediately following broad access to direct-acting antiviral drugs.

The National Institute of Health’s grant funds a phase 2 clinical trial of doxycycline in a large group of individuals with the 2 conditions who are smokers or used to smoke.

The FDA approved lenacapavir, which is the first approval of a drug in a new class of antiretrovirals for the treatment of HIV-1 called capsid inhibitors.

Although quality of life has significantly improved for patients with HIV, there are several factors influencing how we provide care and treat patients now and in the future.

Implants could produce and deliver monoclonal anti-HIV antibody therapy for at least 1 year.

Dena Dillon, HIV clinical pharmacy specialist at the University of Iowa Health Care, discusses 2-drug regimens for individuals living with HIV.

Due to the correlation between virologic suppression and antiretroviral therapy adherence, understanding the impediments of adherence is of the utmost importance.

The findings could also help explain why certain comorbidities persist following other viral infections, including COVID-19.

The 2022 theme is “Putting Ourselves to the Test: Achieving Equity to End HIV.”

Study results show that patients with moderate or severe immune suppression should be considered a priority for additional vaccine doses and risk-reduction strategies.

Changes in DNA methylation may lead to accelerated aging in patients with cancer and HIV.

Approximately 80% of all HIV infections among teens are from the gay and bisexual population.

Although fentanyl is potent and often deadly, it is not passively absorbed into the bloodstream.